Recombinant Human LBP

Recombinant human LBP (Lipopolysaccharide-Binding Protein) offers several compelling advantages for research applications, particularly in studying innate immunity, bacterial infections, and inflammatory responses.

Key Scientific Advantages

Functional Characterization and Mechanism Studies

Recombinant human LBP enables precise investigation of how this protein binds to the lipid A portion of lipopolysaccharide (LPS) to facilitate LPS monomerization and catalyze the binding of LPS monomers to CD14, thereby promoting LPS-induced immune responses. This allows you to study the molecular mechanisms of endotoxin recognition and the subsequent inflammatory cascade with well-defined, reproducible reagents.

Diagnostic and Biomarker Applications

LBP serves as a valuable biomarker for inflammatory disorders and systemic inflammation. Recombinant forms enable standardized assay development for detecting acute phase responses, where LBP concentrations can increase up to 30-fold during infection or inflammation. This makes it particularly useful for developing diagnostic assays and understanding disease progression in conditions such as sepsis, endotoxemia, and various inflammatory states.

Consistency and Reproducibility

Recombinant proteins provide superior batch-to-batch reproducibility and high purity compared to naturally derived proteins. This consistency is essential for obtaining reliable, comparable results across experiments and enabling rigorous quantitative studies of immune cell responses to bacterial endotoxins.

Research Applications

Cellular and Immunological Studies

Recombinant human LBP can be used in bioassays to measure LPS-stimulated cytokine secretion from immune cells, such as IL-8 production by monocytic cells. This allows investigation of how LBP modulates immune cell activation and inflammatory mediator production in response to Gram-negative bacterial infections.

Disease Modeling and Therapeutic Development

The availability of recombinant LBP supports research into septic shock, acute kidney injury, and hepatorenal syndrome, where LBP levels are altered. By using this protein in your experimental models, you can investigate potential therapeutic strategies for modulating host immune responses to severe bacterial infections and antimicrobial resistance scenarios.

Advanced Assay Development

Recombinant human LBP facilitates the development of improved diagnostic and research assays, enabling better characterization of innate immune mechanisms and the role of LBP in various pathological conditions.

You can use recombinant human LBP as a standard for quantification or calibration in your ELISA assays, provided that the recombinant protein is well-characterized, pure, and its concentration is accurately determined.

Supporting details:

• ELISA kits for human LBP commonly use recombinant human LBP as the standard for generating calibration curves. These standards are used to interpolate the concentration of LBP in unknown samples by comparing their optical density (O.D.) values to the standard curve.
• Assay specificity: Most commercial ELISA kits are validated to recognize both natural and recombinant human LBP, ensuring that quantification using a recombinant standard is accurate for both sample types.
• Best practices: For reliable quantification:
  • Use a highly purified recombinant LBP with a known concentration, ideally quantified by an orthogonal method such as HPLC or amino acid analysis.
  • Prepare a fresh standard curve for each assay run, as recommended in ELISA protocols.
  • Ensure the recombinant LBP is in a compatible buffer and does not contain interfering substances.
• Limitations: If your ELISA kit or protocol specifically states that it is not validated for recombinant proteins, or if the recombinant LBP differs significantly in post-translational modifications or folding from the native protein, quantification accuracy may be affected. Always consult the kit datasheet and, if possible, perform a validation experiment comparing recombinant and native LBP recovery.

Summary:
Recombinant human LBP is widely accepted and routinely used as a standard for ELISA quantification and calibration, as long as it is pure, well-characterized, and compatible with your assay system. Always verify compatibility with your specific ELISA kit and validate if using a new recombinant preparation.

Recombinant Human LBP (Lipopolysaccharide Binding Protein) has been validated primarily for use in bioassays, especially those investigating LPS-induced immune responses, and as a functional reagent in cell culture and ELISA standards.

Key validated applications in published research:

• Bioassays:
  Recombinant Human LBP is widely used to study its ability to bind LPS and enhance LPS-stimulated cytokine secretion (e.g., IL-8 in THP-1 monocytic cells). It is employed to model and quantify LPS-induced immune activation, including monocyte and neutrophil responses, and to investigate the modulation of inflammatory signaling pathways (such as Toll-like receptor signaling).

• Cell and Tissue Culture:
  LBP is used to modify cellular sensitivity to LPS in vitro, facilitating studies of innate immune activation and LPS detoxification mechanisms. It is recommended for use with carrier proteins (e.g., BSA) for optimal stability in cell culture applications.

• ELISA Standard:
  Recombinant LBP serves as a standard for quantifying LBP levels in biological samples via ELISA, supporting research into its role as a biomarker for sepsis, acute kidney injury, and other inflammatory conditions.

• Functional Characterization:
  Validated for measuring enhancement of LPS-induced cytokine responses, such as IL-8 secretion, and for studying LBP’s role in transferring LPS to CD14 or HDL, which is relevant for LPS detoxification and immune modulation.

• SDS-PAGE and HPLC:
  Used for protein characterization and purity assessment in biochemical studies.

Representative published research applications:

• Prediction of acute kidney injury and hepatorenal syndrome in cirrhotic patients:
  LBP, in combination with other markers, is validated as a biomarker in clinical prediction models.

• Innate immune profiling in systemic mastocytosis and other diseases:
  Used to assess altered immune responses in patient blood samples.

• Studies of neutrophil extracellular trap formation and platelet function:
  LBP is used to probe its role in immune cell activation and thrombosis.

• Modulation of pro-inflammatory responses in oral keratinocytes and airway epithelial cells:
  Validated for investigating LBP’s effect on Toll-like receptor signaling and cytokine production.

Additional validated uses:

• Blocking Assays:
  Recombinant LBP is validated for use in blocking assays to study LPS-dependent signaling.

• Phospholipid transport studies:
  Used to investigate LBP’s catalytic role in transferring LPS to HDL and phospholipids.

Summary Table:

In summary, recombinant human LBP is a validated reagent for bioassays, cell culture, ELISA standards, and protein characterization, with published research supporting its use in studies of LPS-induced immune responses, biomarker quantification, and innate immunity.

Reconstitution of Recombinant Human LBP Protein

Reconstituting recombinant human LBP requires careful attention to buffer selection, concentration, and handling techniques to maintain protein integrity and biological activity.

Buffer Selection and Initial Reconstitution

Reconstitute the lyophilized protein using sterile distilled water or sterile phosphate-buffered saline (PBS) containing at least 0.1% human or bovine serum albumin (BSA). The recommended reconstitution concentration ranges from 0.1–1.0 mg/mL, though specific protocols may vary. For example, some preparations recommend reconstituting at 50 μg/mL or 100 μg/mL in PBS with carrier protein.

Handling During Reconstitution

Before opening the vial, centrifuge the tube to collect all lyophilized material at the bottom. During reconstitution, avoid vigorous vortexing or forceful pipetting, as these actions can denature the protein and cause foaming. Instead, allow the vial to reconstitute for 15–30 minutes at room temperature with gentle agitation.

Carrier Proteins and Stabilizers

For long-term storage and to maintain protein stability at low concentrations, add carrier proteins such as 0.1% BSA, 5% human serum albumin (HSA), or 10% fetal bovine serum (FBS). For serum-free culture or in vivo experiments where animal proteins must be avoided, use trehalose as a stabilizer instead.

Storage Protocols

Short-term Storage

After reconstitution, store the protein at 4°C for 2–7 days if immediate use is planned. This timeframe is suitable for experiments with a 5–7 day cycle, such as dendritic cell maturation studies.

Long-term Storage

For extended storage, aliquot the reconstituted protein and freeze at –20°C or –80°C (–80°C is recommended for optimal stability). When preparing for long-term storage, add 5–50% glycerol (final concentration) to the reconstituted solution before aliquoting. Although lyophilized protein is stable at room temperature for approximately 3 weeks, store desiccated powder below –18°C.

Critical Handling Considerations

Prevent freeze-thaw cycles, as repeated freezing and thawing can compromise protein function. When removing aliquots during the experimental period, withdraw only the amount needed and return the remainder to storage without re-freezing the entire vial.

Preparation for Cell Culture Applications

For cell culture experiments, use fresh reconstituted protein without prolonged storage, as protein degradation and denaturation may occur and lead to inaccurate results. Dilute the reconstituted stock solution with appropriate culture medium or buffers immediately before adding to cells. The specific dilution will depend on your experimental requirements and the desired final concentration in culture wells.